Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States.
other · Level IV
Where this comes from
- Record sourced from PubMed, PMID 32282879.
- Also identified by DOI 10.1093/cid/ciaa362 and PMC identifier 8563211.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.
Medical subject headings
- Hepacivirus
- Hepatitis C